Singapore, June 24 -- China-based Abbisko Therapeutics has entered into a strategic research collaboration and licence agreement with US-based Eli Lilly and Company to discover and develop innovative medicines across multiple targets.

The agreement builds on the companies' existing relationship and expands Abbisko's role as a China-based biopharma company with global discovery and development ambitions. Under the collaboration, Abbisko will conduct discovery and early development activities for novel drug programmes directed against disease targets selected by Lilly.

This is relevant because early-stage drug discovery partnerships remain an important route for Asia-based biopharma companies to access global development expertise, commer...